DOCSLIB.ORG

20 13 Rep Or T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
20 13 Rep Or T 2013 REPORT More Than 240 Medicines in Development for Leukemia, Lymphoma and Other Blood Cancers Every 4 minutes a person is diagnosed with leukemia, Medicines in Development lymphoma or For Leading Blood Cancers myeloma; Accounting for Application Submitted 9% of all cancers Phase III diagnosed each year Phase II Biopharmaceutical research companies • 15 each for myeloproliferative neo- Phase I are developing 241 medicines for blood plasms, such as myelofibrosis, poly- cancers—leukemia, lymphoma and cythemia vera and essential throm- 97 98 myeloma. This report lists medicines in bocythemia; and for myelodysplastic human clinical trials or under review by syndromes, which are diseases affect- the U.S. Food and Drug Administration ing the blood and bone marrow. (FDA). These medicines in development offer The medicines in development include: hope for greater survival for the thou- sands of Americans who are affected by • 98 for lymphoma, including Hodgkin these cancers of the blood. and non-Hodgkin lymphoma, which 52 affect nearly 80,000 Americans each Definitions for the cancers listed in this year. report and other terms can be found on page 27. Links to sponsor company web • 97 for leukemia, including the four sites provide more information on the major types, which affect nearly potential products. 50,000 people in the United States 24 each year. For information on the value of medi- cines, an in-depth look at current in- • 52 for myeloma, a cancer of the novation and key medical breakthroughs plasma cells, which impacts more benefiting blood cancer patients, please than 22,000 people each year in the see Medicines in Development for Leu- United States. kemia and Lymphoma 2013—Overview. emia • 24 medicines are targeting hema- tological malignancies, which affect Leuk ymphoma Myeloma L bone marrow, blood and lymph Malignancies Hematological nodes. Medicines in Development for Leukemia & Lymphoma Hematological Malignancies Product Name Sponsor Indication Development Phase* Adcetris® Millennium Pharmaceuticals treatment of CD30-positive Phase II brentuximab vedotin Cambridge, MA hematological malignancies millennium.com (Orphan Drug) Seattle Genetics (see also lymphoma) seattlegenetics.com Bothell, WA AMG 319 Amgen hematological malignancies Phase I (PI3K-delta inhibitor) Thousand Oaks, CA amgen.com anti-CD22 antibody-drug Genentech hematological malignancies Phase II conjugate South San Francisco, CA (see also lymphoma) gene.com (DCDT 2980S) anti-CD79b antibody-drug Genentech hematological malignancies Phase II conjugate South San Francisco, CA (see also lymphoma) gene.com (DCDS 4501A) AR-42 Arno Therapeutics hematological malignancies Phase I/II (pan-DAC inhibitor) Flemington, NJ arnothera.com AZD1208 AstraZeneca hematological malignancies Phase I (PIM kinase inhibitor) Wilmington, DE astrazeneca.com AZD9150 AstraZeneca hematological malignancies Phase I (STAT3 inhibitor) Wilmington, DE astrazeneca.com belinostat Spectrum Pharmaceuticals hematological malignancies Phase I (HDAC inhibitor) Henderson, NV (see also lymphoma) sppirx.com CB3304 Cougar Biotechnology hematological malignancies Phase I (noscapine) Raritan, NJ cougarbiotechnology.com darinaparsin ZIOPHARM Oncology hematological malignancies Phase II (ZIO-101) New York, NY (see also lymphoma, myeloma) ziopharm.com fostamatinib AstraZeneca hematological malignancies Phase II (Syk inhibitor) Wilmington, DE astrazeneca.com Rigel Pharmaceuticals rigel.com South San Francisco, CA GS-9973 Gilead Sciences B-cell hematological malignancies Phase I (Syk inhibitor) Foster City, CA gilead.com *For more information about a specific medicine or company in the report, please click on the provided link. 2 Medicines in Development Leukemia & Lymphoma 2013 Medicines in Development for Leukemia & Lymphoma Hematological Malignancies Product Name Sponsor Indication Development Phase Jakafi® Incyte hematological malignancies Phase II ruxolitinib Wilmington, DE incyte.com MEDI-551 AstraZeneca hematological malignancies Phase II (anti-CD19 mAb) Wilmington, DE astrazeneca.com MedImmune medimmune.com Gaithersburg, MD MLN4924 Millennium Pharmaceuticals hematological malignancies Phase I (pevonedistat) Cambridge, MA millennium.com MLN8237 Millennium Pharmaceuticals hematological malignancies Phase II (alisertib) Cambridge, MA (see also lymphoma) millennium.com MLN9708 Millennium Pharmaceuticals hematological malignancies Phase I (ixazomib) Cambridge, MA (see also myeloma) millennium.com (second-generation proteasome inhibitor) moxetumomab pasudotox AstraZeneca hematological malignancies Phase I (anti-CD22 recombinant Wilmington, DE astrazeneca.com immunotoxin) MedImmune medimmune.com Gaithersburg, MD nivolumab Bristol-Myers Squibb hematological malignancies Phase I (anti-PD-1) Princeton, NJ bms.com oprozomib Onyx Pharmaceuticals hematological malignancies Phase I South San Francisco, CA onyx.com RG7112 Roche hematological malignancies Phase I (MDM2 antagonist) Nutley, NJ roche.com RG7388 Roche hematological malignancies Phase I (proto oncogene protein-c mdm2 Nutley, NJ roche.com inhibitor) SAR405838 Ascenta Therapeutics hematological malignancies Phase I (HDM2/p53 antagonist) Malvern, PA ascenta.com Sanofi US sanofi.com Bridgewater, NJ SAR650984 ImmunoGen hematological malignancies Phase I (anti-CD38 naked mAb) Waltham, MA immunogen.com Sanofi US sanofi.com Bridgewater, NJ Medicines in Development Leukemia & Lymphoma 2013 3 Medicines in Development for Leukemia & Lymphoma Leukemia Product Name Sponsor Indication Development Phase ABT-199/GDC-0199/RG7601 AbbVie relapsed/refractory chronic Phase I (Bcl-2 inhibitor) North Chicago, IL lymphocytic leukemia (CLL) abbvie.com Genentech (see also lymphoma, myeloma) gene.com South San Francisco, CA roche.com Roche Nutley, NJ Actimab-A™ Actinium Pharmaceuticals acute myeloid leukemia (AML) Phase I/II lintuzumab Ac-225 New York, NY actiniumpharmaceuticals.com aminopterin Syntrix Biosystems pediatric acute lymphoblastic Phase II Auburn, WA leukemia (ALL) syntrixbio.com Arzerra® GlaxoSmithKline first-line CLL, relapsed CLL Phase III ofatumumab Rsch. Triangle Park, NC (see also lymphoma) gsk.com (Orphan Drug) AT-101 Ascenta Therapeutics CLL Phase II completed (pan Bcl-2 inhibitor) Malvern, PA (see also lymphoma) ascenta.com AT-406 Ascenta Therapeutics AML Phase I (multi-IAP inhibitor) Malvern, PA ascenta.com Debiopharm debiopharm.com Lausanne, Switzerland bafetinib CytRx CLL Phase II completed Los Angeles, CA cytrx.com BI-811283 Boehringer Ingelheim Pharmaceuticals AML Phase I/II (aurora B kinase inhibitor) Ridgefield, CT boehringer-ingelheim.com BI-836826 Boehringer Ingelheim Pharmaceuticals CLL Phase I Ridgefield, CT boehringer-ingelheim.com BI-836858 Boehringer Ingelheim Pharmaceuticals AML Phase I Ridgefield, CT boehringer-ingelheim.com birinapant TetraLogic Pharmaceuticals AML Phase I/II Malvern, PA (see also lymphoma) tetralogicpharma.com Bismab-A™ Actinium Pharmaceuticals AML Phase I/II lintuzumab Bi-213 New York, NY actiniumpharmaceuticals.com 4 Medicines in Development Leukemia & Lymphoma 2013 Medicines in Development for Leukemia & Lymphoma Leukemia Product Name Sponsor Indication Development Phase blinatumomab Amgen ALL Phase II (AMG 103) Thousand Oaks, CA (see also lymphoma) amgen.com BMS-906024 Bristol-Myers Squibb T-cell ALL Phase I (notch inhibitor) Princeton, NJ (see also lymphoma) bms.com BMS-936564 Bristol-Myers Squibb AML, CLL, diffuse large Phase I (anti-CXCR4) Princeton, NJ B-cell leukemia bms.com (see also lymphoma, myeloma) Bosulif® Pfizer first-line Ph+ chronic myeloid Phase III bosutinib New York, NY leukemia (CML) pfizer.com BP-100-1.01 Bio-Path Holdings ALL, AML, CML Phase I (liposomal Grb-2) Houston, TX (see also myelodysplastic) biopathholdings.com (Orphan Drug) calaspargase pegol Sigma-Tau Pharmaceuticals ALL in adolescents and children Phase III (Orphan Drug) Gaithersburg, MD sigmatau.com CC-292 Celgene CLL Phase I (Btk inhiitor) Summit, NJ (see also lymphoma) celgene.com CC-486 Celgene post-induction AML maintenance Phase II (nucleoside analogue) Summit, NJ (see also myelodysplastic) celgene.com Ceplene® EpiCept AML Phase III histamine Tarrytown, NY epicept.com CNDO-109 Coronado Biosciences AML Phase II (tumor-activated natural Burlington, MA coronadobiosciences.com killer cells) (Orphan Drug) CPX-351 Celator Pharmaceuticals AML Phase III (cytarabine/daunorubicin) Princeton, NJ celatorpharma.com (Orphan Drug) crenolanib AROG Pharmaceuticals AML Phase II (CP-868-596) Dallas, TX arogpharma.com CTL019 Novartis Pharmaceuticals CLL Phase II (CAR T-cell therapy) East Hanover, NJ novartis.com University of Pennsylvania Philadelphia, PA CWP232291 JW Pharmaceutical AML Phase I Seoul, South Korea Medicines in Development Leukemia & Lymphoma 2013 5 Medicines in Development for Leukemia & Lymphoma Leukemia Product Name Sponsor Indication Development Phase Dacogen® Eisai AML application submitted decitabine Woodcliff Lake, NJ eisai.com (Orphan Drug) -------------------------------------- ----------------------------------------- pediatric AML Phase II eisai.com DFP-10917 Delta-Fly Pharma ALL, AML Phase I/II (cell cycle inhibitor) Tokushima, Japan dinaciclib Merck CLL Phase III (SOK inhibitor) Whitehouse Station, NJ merck.com (Orphan Drug) elesclomol Synta Pharmaceuticals AML Phase I Lexington, MA syntapharma.com ENMD-2076 EntreMed AML Phase I completed (Orphan Drug) Rockville, MD (see also myeloma) entremed.com entinostat Syndax Pharmaceuticals leukemia Phase II Waltham, MA (see also lymphoma) syndax.com EPZ-5676 Epizyme leukemia
Load more

Recommended publications
  • For Acute Myeloid Leukemia
    Published OnlineFirst September 21, 2010; DOI: 10.1158/1078-0432.CCR-10-0382 Published OnlineFirst on September 21, 2010 as 10.1158/1078-0432.CCR-10-0382 Clinical Therapy Clinical Cancer Research Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia Todd L. Rosenblat1, Michael R. McDevitt1, Deborah A. Mulford1, Neeta Pandit-Taskar1, Chaitanya R. Divgi1, Katherine S. Panageas1, Mark L. Heaney1, Suzanne Chanel1, Alfred Morgenstern2, George Sgouros1, Steven M. Larson1, David A. Scheinberg1, and Joseph G. Jurcic1 Abstract Purpose: Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid leukemia (AML). To increase the potency of the antibody without the nonspecific cytotoxicity associated with β-emitters, the α-particle–emitting ra- dionuclide bismuth-213 (213Bi) was conjugated to lintuzumab. This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of 213Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy. Experimental Design: Thirty-one patients with newly diagnosed (n = 13) or relapsed/refractory (n = 18) AML (median age, 67 years; range, 37-80) were treated with cytarabine (200 mg/m2/d) for 5 days followed by 213Bi-lintuzumab (18.5-46.25 MBq/kg). Results: The MTD of 213Bi-lintuzumab was 37 MB/kg; myelosuppression lasting >35 days was dose limiting. Extramedullary toxicities were primarily limited to grade ≤2 events, including infusion-related reactions. Transient grade 3/4 liver function abnormalities were seen in five patients (16%). Treatment- related deaths occurred in 2 of 21 (10%) patients who received the MTD.
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • Guide to Treatment Role of Antibodies in Acute Leukemia: Focus on Transplant-Eligible Populations
    PRACTICE AID Guide to Treatment Role of Antibodies in Acute Leukemia: Focus on Transplant-Eligible Populations Acute Myeloid Leukemia DRUG STATUS TARGET DOSE EU EMA approved: In combination with daunorubicin and Induction: 3 mg/m2 (up to 5 mg/m2 in EU and 4.5 mg/m2 in US) cytarabine for pts aged ≥15 y with previously untreated, on d 1, 4, and 7 in combination with daunorubicin and cytarabine de novo CD33+ AML, except APL CD33 Consolidation: 3 mg/m2 (up to 5 mg/m2 in EU and 4.5 mg/m2 in US) Gemtuzumab US FDA approved: Newly diagnosed CD33+ AML in adults and 1,2 on d 1 in combination with daunorubicin and cytarabine ozogamicin pediatric pts aged ≥1 month; R/R CD33+ AML in adults and Please consult label for single-agent dosing and dosing in R/R AML. pediatric pts aged 2 y Phase 3 SIERRA study CD45 Adults aged ≥55 y with active R/R AML, adequate organ Dosimetry directed (SIERRA study) Iomab-B3 function, and related/unrelated matched donor (BC8 mAb linked to radioisotope iodine-131) Acute Lymphoblastic Leukemia EU EMA approved: Adults with R/R CD22+ B-cell ALL; adults Cycle 1 dose: 0.8 mg/m2 on d 1; 0.5 mg/m2 on days 8 and 15 for 21 d 2 Inotuzumab with Ph+ R/R B-cell ALL who failed treatment with at least one TKI CD22 Patients in CR/CRi: 0.5 mg/m on days 1, 8, and 15 for 28 d ozogamicin4,5 US FDA approved: Adults with R/R CD22+ B-cell ALL Patients not in CR/CRi: Use cycle 1 dose for 28 d EU Dose: By patient’s weight (≥45 kg = 9 mcg/d on d 1-7 and 28 mcg/d on EU EMA approved: Adults with B-cell ALL who are in d 8-28; <45 kg = 5 mcg/m2/d on
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • Chemotherapeutic Treatment of Acute Myeloid Leukemia
    Clinical Trial Outcomes Mahdi, Mahdi & Knapper Chemotherapeutic treatment of acute myeloid leukemia 5 Clinical Trial Outcomes Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials Clin. Invest. (Lond.) Better outcomes for patients with acute myeloid leukemia over the last 30 years have Ali J Mahdi*,1, Eamon J been largely achieved by improvements in supportive care measures rather than Mahdi1 & Steven Knapper1 therapeutic advances. The combination of daunorubicin and cytarabine has remained 1Cardiff University School of Medicine, Hematology Department, Heath Park, the standard of care for patients undergoing intensive induction–consolidation Cardiff CF14 4XN, UK treatment. In less fit older patients, low-dose cytarabine is the equivalent, although *Author for correspondence: the hypomethylating agent azacitidine may be challenging current practice. [email protected] Enhanced understanding of disease pathogenesis and therapy resistance has enabled the entry of novel chemotherapeutic and nonchemotherapeutic agents into clinical development with varied levels of activity. This article examines the evidence behind established chemotherapy practices for intensive and nonintensive acute myeloid leukemia treatments with an emphasis on emerging clinical trial data from novel chemotherapeutic and nonchemotherapeutic agents. Keywords: acute myeloid leukemia • aminopeptidase inhibitors • farnesyl transferase inhibitors • FLT3 inhibitors • gemtuzumab ozogamicin • histone deacytylase inhibitors • hypomethylating • Polo-like kinase 1 inhibitors Methodology AML cases [7]. Older patients over the age of 10.4155/CLI.14.112 An electronic database search (EMBASE, 60 years thus represent an important popula- MEDLINE and PubMed) was undertaken tion from both demographic and therapeutic to identify and review clinical studies in perspectives. Older patients frequently have acute myeloid leukemia (AML) undertaken multiple comorbidities, unfavorable cyto- between 1 January 2009 and 1 June 2014.
    [Show full text]
  • TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (Egfrt)
    (19) TZZ _T (11) EP 2 496 698 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 14/71 (2006.01) C12N 9/12 (2006.01) 09.01.2019 Bulletin 2019/02 (86) International application number: (21) Application number: 10829041.2 PCT/US2010/055329 (22) Date of filing: 03.11.2010 (87) International publication number: WO 2011/056894 (12.05.2011 Gazette 2011/19) (54) TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION VERKÜRZTER REZEPTOR FÜR DEN EPIDERMALEN WACHSTUMSFAKTOR-REZEPTOR ZUR AUSWAHL UMGEWANDELTER T-ZELLEN RÉCEPTEUR DU FACTEUR DE CROISSANCE DE L’ÉPIDERME TRONQUÉ (EGFRT) POUR LA SÉLECTION DE LYMPHOCYTES T TRANSDUITS (84) Designated Contracting States: • LI ET AL.: ’Structural basis for inhibition of the AL AT BE BG CH CY CZ DE DK EE ES FI FR GB epidermal growth factor receptor by cetuximab.’ GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO CANCER CELL vol. 7, 2005, pages 301 - 311, PL PT RO RS SE SI SK SM TR XP002508255 • CHAKRAVERTY ET AL.: ’An inflammatory (30) Priority: 03.11.2009 US 257567 P checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral (43) Date of publication of application: tissues.’ JEM vol. 203, no. 8, 2006, pages 2021 - 12.09.2012 Bulletin 2012/37 2031, XP008158914 • POWELL ET AL.: ’Large-Scale Depletion of (73) Proprietor: City of Hope CD25+ Regulatory T Cells from Patient Duarte, CA 91010 (US) Leukapheresis Samples.’ J IMMUNOTHER vol. 28, no.
    [Show full text]
  • Multiple Myeloma and Engineered Cell Therapy
    Multiple Myeloma and Engineered Cell Therapy Sarah M. Larson, MD Assistant Professor of Medicine September 2018 Spectrum of Disease Morgan GJ Nat Cancer Rev 2012 SMM: Janssen SMM3001 • Patients randomized to dara sc vs active monitoring •Study duration 8 years • Primary endpoint PFS • Prior SMM treatment is an exclusion • NCT03301220 Van de Donk NWCJ Immunol Rev 2016 Multiple Myeloma • Second most common heme malignancy • 33,000 new cases 2017 • >100,000 people with multiple myeloma • Increasing number of patients • Incidence • Improved survival SEER database Treatment Treatment of Initial Consolidation/ ASCT relapsed Therapy Maintenance disease Supportive Care Minimal Residual Disease (MRD) Undetectable MRD: The Goal of Frontline Therapy? PFS OS Landgren O BMT 2016 IFM2009 • Newly diagnosed patients eligible for transplant • Patients <65 years of age PFS 50 mos (p<0.001) CR 59% Transplant MRD neg 79% (p<0.001) R 2 cycles A Len Main RVD N 3 D Cycles O RVD M PFS 36 mos I CR 48% Z MRD neg 65% E 5 Cycles D RVD Len Main Attal M NEJM 2017 Response at Each Treatment Phase Treatment Arm Induction Consolidation Maintenance (%) (%) (%) RVD 45 69 76 Transplant 47 78 85 Attal M NEJM 2017 Conclusions • Transplant remains a standard therapy • Delayed transplant is reasonable • Collection and storage of stem cell frequently not covered • Following second line of treatment • Trials to improve the transplant course Stem Cell Mobilization Trial • BL-8040 Phase III, randomized, double-blinded, placebo controlled trial of BL-8040 and G-CSF vs G- CSF and
    [Show full text]
  • Actinium Pharmaceuticals, Inc
    Actinium Pharmaceuticals, Inc. ATNM: NYSE AMERICAN November 2019 Disclaimer and Safe Harbor The information presented herein contains express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc. (“Actinium”) that are not historical facts. These forward- looking statements include statements regarding Actinium’s expectations for its product candidates (including their therapeutic and commercial potential, anticipated future development activities, anticipated timing of development activities, including initiation of clinical trials and presentations of clinical data and the indications Actinium and its collaborators plan to pursue), future results of operations and financial position, business strategy, strategic collaborations, any royalty or milestone payments and Actinium’s ability to obtain and maintain intellectual property protection for its product candidates. Such forward-looking statements may be identified by words such as “believes”, “may”, “will”, “expects”, “endeavors”, “anticipates”, “intends”, “plans”, “estimates”, “projects”, “should”, “objective” and variations of such words and similar words. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential
    [Show full text]
  • Draft COMP Agenda 16-18 January 2018
    12 January 2018 EMA/COMP/818236/2017 Inspections, Human Medicines Pharmacovigilance and Committees Committee for Orphan Medicinal Products (COMP) Draft agenda for the meeting on 16-18 January 2018 Chair: Bruno Sepodes – Vice-Chair: Lesley Greene 16 January 2018, 09:00-19:30, room 2F 17 January 2018, 08:30-19:30, room 2F 18 January 2018, 08:30-18:30, room 2F Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised. Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
    [Show full text]
  • WO 2010/135468 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 25 November 2010 (25.11.2010) WO 2010/135468 Al (51) International Patent Classification: [US/ES]; C/ Rio EsIa 77 PO2 A Villamayor, E-37007 GOlN 33/50 (2006.01) Salamanca (ES). LAGO, Santiago [GB/ES]; C/ Fernando Camino 15 3-E, E-29016 Malaga (ES). MATOSES, (21) International Application Number: Maria [ES/ES]; C/ Los Cristos 1 1 C, E-29008 Malaga PCT/US2010/035474 (ES). SUAREZ, Lilia [ES/ES]; C/ Ancla, 27 Casa 13, (22) International Filing Date: E-29720 CaIa Del Moral (ES). SAPIA, Sandra [IT/ES]; 19 May 2010 (19.05.2010) C/ Zapateros, 2 2 C, E-29005 Malaga (ES). BOSAN- QUET, Andrew [GB/GB]; 4 The Brow, Church Road, English (25) Filing Language: Combe Down, BA2 5JL, Bath (GB). GOR- (26) Publication Language: English ROCHATEGUI, Julian [ES/ES]; C/Puerto de los Leones 5, Majadahonda, E-28220 Madrid (ES). (30) Priority Data: TUDELA, Consuelo [ES/ES]; Av. Juan Carlos I 23, M a 61/179,685 19 May 2009 (19.05.2009) US jadahonda, E-28220 Madrid (ES). HERNANDEZ, Pilar (71) Applicant (for all designated States except US): VIVIA [ES/ES]; C/Uruguay 16, E-37OO3 Salamanca (ES). BIOTECH S.L. [ES/ES]; C/ Menendez Pelayo 12, 3d, CAVEDA, Luis Ignacio [ES/ES]; Av. Valladolid 17, E-47001 Valladolid (ES). E-28008 Madrid (ES). (72) Inventors; and (74) Agent: MALLON, Joseph, J.; Knobbe Martens Olson & (75) Inventors/Applicants (for US only): BALLESTEROS, Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA Juan [ES/ES]; C/ Espalter 8 - 7 B, E-28014 Madrid (ES).
    [Show full text]
  • Leukemia I N S I G H T S VOL
    Leukemia INSIGHTS VOL. 17 • NO. 1 SPRING 2012 Slow Motion Breakthroughs in Adult ALL Therapy With a recent wave of new, highly active monoclonal for ALL is poor, however, with complete response antibodies and of a new BCR-ABL tyrosine kinase rates of 20 percent to 30 percent, depending on inhibitor (ponatinib), we are at the brink of prior therapy and duration of first remission. therapeutic breakthroughs which will significantly Median disease-free survival ranges from 2 to improve survival of adult acute lymphocytic 7.5 months. Long-term survival after ALL salvage leukemia (ALL). therapy is less than 10 percent. In this issue of Adult ALL encompasses a heterogeneous group Leukemia Insights, we focus on newer investigational of lymphoid malignancies. The two predominant strategies in adult ALL. subtypes are B-ALL and T-ALL, based on expression of B-lineage or T-lineage markers. Prognosis is New Monoclonal Antibodies in Pre-B ALL related to age, karyotype, molecular profile, immu- nophenotype, and other disease features. Prognosis The targeting of CD20 in ALL with combinations for pediatric ALL has improved significantly in the of rituximab and chemotherapy has improved past several decades; the current long-term survival survival in Burkitt leukemia and in CD20+ ALL. rate is greater than 80 percent. Long-term survival In the same light, several conjugated and unconjugated in adult ALL is 35 percent to 40 percent. The most monoclonal antibodies targeting CD22 and CD19 common reason for failure is disease recurrence. are under study as almost all ALL leukemic cells The hyper-CVAD regimen (hyperfractionated also express these markers.
    [Show full text]
  • A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure 2013-0870
    Protocol Page A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure 2013-0870 Core Protocol Information Short Title Omacetaxine in Patients with Intermediate-1 and Higher Risk MDS post HMA Failure Study Chair: Elias Jabbour Additional Contact: Jhinelle L. Graham Vicky H. Zoeller Leukemia Protocol Review Group Additional Memo Recipients: Recipients List OPR Recipients (for OPR use only) None Study Staff Recipients None Department: Leukemia Phone: 713-792-4764 Unit: 0428 Full Title: A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure Protocol Type: Standard Protocol Protocol Phase: Phase II Version Status: Activated -- Closed to new patient entry as of 08/05/2018 Version: 08 Document Status: Saved as "Final" Submitted by: Vicky H. Zoeller--9/11/2017 12:24:33 PM OPR Action: Accepted by: Margaret Okoloise -- 9/14/2017 12:09:50 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) Protocol Body 2013-0870 March 6, 2017 1 A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure 2013-0870 March 6, 2017 2 Table of Contents 1.0 Objectives .................................................................................................. 3 2.0 Background ..............................................................................................
    [Show full text]